Fluidigm Announces First Multimodal Single-Cell Application for the C1
Offering a new assay to measure transposase-accessible chromatin (ATAC) and T cell receptor (TCR) reporter gene expression from each cell, the new T-ATAC-seq application provides a powerful tool to uncover new insights in the development of the immune system and its role in a range of human diseases.
The C1 system offers the widest menu of unique single-cell applications, enabling deep profiling of single cells within complex enriched or non-enriched cell populations. Used by hundreds of laboratories around the world, C1 captures and processes each single cell using proprietary microfluidics technology, maximizing molecular detection sensitivity. When using C1 together with the C1 Open App™ application, researchers also have the unique ability to build new innovative applications that go beyond conventional single-cell mRNA sequencing.
Single-cell researchers seek to gain an understanding of genome-wide chromatin accessibility while at the same time maintaining and measuring RNA expression. Taking advantage of the open protocol and script development feature and C1 Open App integrated fluidic circuits,
“T-ATAC-seq allows for unprecedented molecular views of antigen-specific T cells by pairing measurements of T cell receptor sequence with chromatin accessibility genome-wide in single cells,” said Satpathy. “The development of this technology was really enabled by the C1 Open App system, where we could easily design nanoliter-scale single-cell reactions in silico, implement them in Script Builder™, and then within hours test them in the laboratory.”
T-ATAC-seq is the 21st single-cell method enabled on the C1 system, including RNA sequencing, targeted gene expression, miRNA profiling, whole genome and exome sequencing, targeted gene sequencing, and epigenetic applications. Applications available on Script Hub are open to the C1 research community and are compatible with any C1 system. Each application includes the protocol, reference data, script, and links to publications.
“Providing a full 360-degree view of the cell, the C1 is the cornerstone for laboratories around the world to deeply characterize cell phenotypes at single-cell resolution,” said
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm),
Forward-Looking Statement for
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and development of additional products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to uncertainties in contractual relationships; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation